NCT03314636View on ClinicalTrials.gov

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2026

Conditions
Myeloma
Interventions
DRUG

Carfilzomib

See in arm description

DRUG

Lenalidomide

See in arm description

DEVICE

PET-CT

See in arm description

DRUG

Dexamethasone

See in arm description

Trial Locations (4)

Unknown

Copenhagen University Hospital, Rigshospitalet, Copenhagen

Odense University Hospital, Odense

Oslo University Hospital, Oslo

Skåne University Hospital, Lund

All Listed Sponsors
collaborator

Nordic Myeloma Study Group

OTHER

lead

Oslo University Hospital

OTHER